NCT06987318 is a Phase 1 clinical trial of VRC07-523LS in HIV-1-infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Who is sponsoring NCT06987318?

NCT06987318 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What drugs are being tested in NCT06987318?

Interventions in NCT06987318: VRC07-523LS, PGT121.414.LS.

What condition does NCT06987318 study?

NCT06987318 studies HIV-1-infection.

Is NCT06987318 still recruiting?

NCT06987318 is currently not yet recruiting. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT06987318

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

Not yet recruiting Phase 1 Last updated 3 April 2026

What this trial tests

Phase 1 trial testing VRC07-523LS in HIV-1-infection in 40 participants. Not yet recruiting.

Timeline

12 June 2026

Primary endpoint
29 August 2027

7 May 2028

Quick facts

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	12 June 2026
Primary completion	29 August 2027
Estimated completion	7 May 2028
Sites	13 locations across United States, Brazil, Peru

Drugs / interventions tested

VRC07-523LS — full drug profile →
PGT121.414.LS — full drug profile →

Conditions studied

HIV-1-infection — all drugs for HIV-1-infection →

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Who can join

Adults 18 to 70, any sex, with HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, and efficacy of combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

mRNA-Encoded Antibodies: An Emerging Paradigm in Antiviral Protection.
Klotchenko S, Plotnikova M. · · 2026 · PMID 41750365 · DOI 10.3390/biom16020297

Verify or expand the search:

Other trials of VRC07-523LS

Trials testing the same drug.

NCT06517693 — Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1 · Phase 1 · recruiting
NCT06484335 — RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV · Phase 1 · recruiting
NCT06508749 — The Tatelo Plus Study · Phase 1, PHASE2 · recruiting
NCT05719441 — A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation Dur · Phase 2 · recruiting
NCT05769569 — Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission · Phase 1 · withdrawn

Other recruiting trials for HIV-1-infection

Currently open trials in the same condition.

NCT07293559 — Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States · recruiting
NCT06919016 — A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1- · Phase 1 · active not recruiting
NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV · Phase 2 · recruiting
NCT06774872 — Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Succes · Phase 2 · recruiting
NCT06890988 — Ending the Epidemic Interventions in the Dental Setting - UH3 · NA · recruiting

Other National Institute of Allergy and Infectious Diseases (NIAID) trials

Trials by the same sponsor.

NCT07216794 — Small Trial of Alendronate Impact on the Reservoir of HIV · Phase 2 · not yet recruiting
NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT07124559 — A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of · Phase 1, PHASE2 · not yet recruiting
NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction · Phase 1 · not yet recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06987318 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID)
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06987318.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing